Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro

被引:35
作者
Kim, Soochi [1 ,2 ]
Gwak, HyeRan [2 ,3 ]
Kim, Hee Seung [2 ,4 ]
Kim, Boyun [2 ,5 ]
Dhanasekaran, Danny N. [6 ]
Song, Yong Sang [1 ,2 ,3 ,4 ]
机构
[1] Seoul Natl Univ, Coll Med, Interdisciplinary Program Canc Biol, Seoul, South Korea
[2] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
[3] Seoul Natl Univ, Dept Agr Biotechnol, Biomodulat, Seoul, South Korea
[4] Seoul Natl Univ, Dept Obstet & Gynecol, Seoul, South Korea
[5] Seoul Natl Univ, Nano Syst Inst, Seoul, South Korea
[6] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Norman, OK USA
基金
新加坡国家研究基金会; 美国国家卫生研究院;
关键词
ascites; migration; invasion; IL-6R; ovarian cancer; EPITHELIAL-MESENCHYMAL TRANSITION; TRAIL-INDUCED APOPTOSIS; CARCINOMA CELLS; INTERLEUKIN-6; METASTASIS; EXPRESSION; GENE; PROGRESSION; INHIBITION; PATHWAY;
D O I
10.18632/oncotarget.13074
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transcoelomic route is the most common and the earliest route of metastasis, causing the ascites formation in advanced epithelial ovarian cancer (EOC). We demonstrated that interleukin 6 (IL-6) is enriched in the malignant ascites from patients with ovarian cancer, which enhanced invasive properties of EOC cells. Interestingly, the expression of IL-6R on cell membrane of EOC cells correlated with ascites-induced invasion. Selective knockdown of IL-6R or inhibition with IL-6 neutralizing antibody, suppressed the stimulatory effects of ascites on EOC invasion. Moreover, the ascites treatment induced the phosphorylation of JAK2-STAT3 and use of selective inhibitors of JAK2 and STAT3, blocked the expression of epithelial-mesenchymal transition related proteins in parallel with the suppression of EOC invasion. Thus, IL-6/IL-6R mediated JAK2-STAT3 signaling pathway could be a promising therapeutic target for anticancer therapy in ovarian cancer patients with ascites.
引用
收藏
页码:83148 / 83159
页数:12
相关论文
共 34 条
[1]   Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research [J].
Ahmed, Nuzhat ;
Stenvers, Kaye L. .
FRONTIERS IN ONCOLOGY, 2013, 3
[2]   Pattern and prognostic factors in patients with malignant ascites: a retrospective study [J].
Ayantunde, A. A. ;
Parsons, S. L. .
ANNALS OF ONCOLOGY, 2007, 18 (05) :945-949
[3]   Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins [J].
Carduner, L. ;
Leroy-Dudal, J. ;
Picot, C. R. ;
Gallet, O. ;
Carreiras, F. ;
Kellouche, S. .
CLINICAL & EXPERIMENTAL METASTASIS, 2014, 31 (06) :675-688
[4]   The bright side of ascites in ovarian cancer [J].
Cohen, Marie ;
Petignat, Patrick .
CELL CYCLE, 2014, 13 (15) :2319-2319
[5]   Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas [J].
Colomiere, M. ;
Ward, A. C. ;
Riley, C. ;
Trenerry, M. K. ;
Cameron-Smith, D. ;
Findlay, J. ;
Ackland, L. ;
Ahmed, N. .
BRITISH JOURNAL OF CANCER, 2009, 100 (01) :134-144
[6]   Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer [J].
Coward, Jermaine ;
Kulbe, Hagen ;
Chakravarty, Probir ;
Leader, David ;
Vassileva, Vessela ;
Leinster, D. Andrew ;
Thompson, Richard ;
Schioppa, Tiziana ;
Nemeth, Jeffery ;
Vermeulen, Jessica ;
Singh, Naveena ;
Avril, Norbert ;
Cummings, Jeff ;
Rexhepaj, Elton ;
Jirstrom, Karin ;
Gallagher, William M. ;
Brennan, Donal J. ;
McNeish, Iain A. ;
Balkwill, Frances R. .
CLINICAL CANCER RESEARCH, 2011, 17 (18) :6083-6096
[7]   Regulatory networks defining EMT during cancer initiation and progression [J].
De Craene, Bram ;
Berx, Geert .
NATURE REVIEWS CANCER, 2013, 13 (02) :97-110
[8]  
Giuntoli RL, 2009, ANTICANCER RES, V29, P2875
[9]   Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis [J].
Goncharenko-Khaider, Nadzeya ;
Matte, Isabelle ;
Lane, Denis ;
Rancourt, Claudine ;
Piche, Alain .
MOLECULAR CANCER, 2012, 11
[10]   Interleukin-6 signaling pathway in targeted therapy for cancer [J].
Guo, Yuqi ;
Xu, Feng ;
Lu, Tianjian ;
Duan, Zhenfeng ;
Zhang, Zhan .
CANCER TREATMENT REVIEWS, 2012, 38 (07) :904-910